FOCAL EPILEPSY
Researching an investigational treatment option for Focal Onset Epilepsy
What to Expect
If you qualify and are enrolled in the study, you will receive the following at no cost:
The investigational medication, or a placebo
- All study-related care, testing, and monitoring
- Ongoing appointments with the study doctors and qualified medical providers specializing in neurological care
You will continue to see your regular doctors for routine office visits and checkups.
The study will consist of a screening visit, 8-week observation phase, followed by an 8 to 12-week double blind treatment phase, and possible 2-week follow-up.
The double-blind phase includes study visits at day 1, and weeks 2, 4, 8, and 12 to assess the efficacy, safety and tolerability of BHV-7000.
All participants who complete the double-blind phase of the study will have the opportunity to enroll in a separate long-term safety study where all participants will receive BHV-7000 and study-related care, at no cost.
Participants who do not opt-in to the long-term safety study will enter the follow-up phase of this study for an assessment approximately 2 weeks after their last dose of study medication or placebo.
4
Questions
1
Minute
Take our short self assessment.
In approximately a minute, you can see if you qualify for our study.
Your personal information and your answers to the study questions are only used for the purposes of determining if the clinical study is suitable for you. You can at any time withdraw your consent and have your personal data removed.